Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Premium

Premium: US FDA Warning Letter to IPCA Laboratories for Ratlam facility, Pithampur facility and Piparia Silvassa facility

 

On the 29-Jan-16 (Tuesday), the US FDA issued a Warning Letter to IPCA Laboratories. 

The letter was in relation to the:

Inspection performed during July, 2014 at Ratlam (Madhya Pradesh) observations in Form FDA 483 which subsequently resulted into issuance of import alert on the said manufacturing unit by the US FDA on 22-Jan-15 Inspection of the formulations manufacturing units situated at SEZ Indore (Pithampur) and Piparia (Silvassa) which resulted in Form . . .

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial